O	0	5	Fatty
O	6	10	acid
O	11	19	profiles
O	20	22	in
O	23	34	erythrocyte
O	35	44	membranes
O	45	54	following
O	55	58	the
B-intervention	59	72	Mediterranean
I-intervention	73	77	diet
O	78	79	-
O	80	84	data
O	85	89	from
O	90	91	a
O	92	103	multicenter
O	104	113	lifestyle
O	114	126	intervention
O	127	132	study
O	133	135	in
O	136	141	women
O	142	146	with
O	147	157	hereditary
O	158	164	breast
O	165	171	cancer
O	172	173	(
O	173	178	LIBRE
O	178	179	)
O	179	180	.

O	181	189	Evidence
O	189	190	-
O	190	195	based
O	196	204	concepts
O	205	207	to
O	208	215	prevent
O	216	222	breast
O	223	229	cancer
O	230	232	in
O	233	238	women
O	239	243	with
O	244	249	BRCA1
O	249	250	/
O	250	251	2
O	252	261	mutations
O	262	265	are
O	266	273	limited
O	273	274	.

O	275	284	Adherence
O	285	287	to
O	288	289	a
O	290	303	Mediterranean
O	304	308	diet
O	309	310	(
O	310	314	MedD
O	314	315	)
O	316	319	has
O	320	324	been
O	325	335	associated
O	336	340	with
O	341	342	a
O	343	348	lower
O	349	353	risk
O	354	357	for
O	358	364	breast
O	365	371	cancer
O	371	372	,
O	373	381	possibly
O	382	385	due
O	386	388	to
O	389	390	a
O	391	400	favorable
O	401	406	fatty
O	407	411	acid
O	412	413	(
O	413	415	FA
O	415	416	)
O	417	423	intake
O	423	424	.

O	425	429	Here
O	429	430	,
O	431	433	we
O	434	441	studied
O	442	444	in
O	445	447	an
O	448	450	at
O	450	451	-
O	451	455	risk
O	456	466	population
O	467	470	the
O	471	477	effect
O	478	480	of
O	481	482	a
O	483	492	lifestyle
O	493	505	intervention
O	506	510	that
O	511	519	included
O	520	523	the
O	524	528	MedD
O	529	531	on
O	532	534	FA
O	535	546	composition
O	547	549	in
O	550	553	red
O	554	559	blood
O	560	564	cell
O	565	574	membranes
O	575	576	(
O	576	580	RBCM
O	580	581	)
O	581	582	.

O	583	587	Data
O	588	595	derived
O	596	600	from
O	601	604	the
B-location	605	611	German
O	612	623	multicenter
O	624	629	trial
O	630	635	LIBRE
O	635	636	,
O	637	641	from
O	642	647	which
B-total-participants	648	650	68
O	651	656	women
O	657	661	were
O	662	672	randomized
O	673	677	into
O	678	680	an
O	681	693	intervention
O	694	699	group
O	700	701	(
O	701	703	IG
O	703	704	)
O	705	712	trained
O	713	716	for
O	717	721	MedD
O	722	725	and
O	726	735	increased
O	736	744	physical
O	745	753	activity
O	754	757	for
O	758	760	12
O	761	767	months
O	767	768	,
O	769	772	and
O	773	774	a
B-control	775	780	usual
I-control	781	785	care
I-control	786	793	control
I-control	794	799	group
O	800	801	(
O	801	803	CG
O	803	804	)
O	804	805	.

O	806	815	Adherence
O	816	818	to
O	819	822	the
O	823	827	diet
O	828	831	was
O	832	840	assessed
O	841	846	after
O	847	848	3
O	849	852	and
O	853	855	12
O	856	862	months
O	863	868	using
O	869	872	the
O	873	882	validated
O	883	896	Mediterranean
O	897	901	Diet
O	902	911	Adherence
O	912	920	Screener
O	921	922	(
O	922	927	MEDAS
O	927	928	)
O	929	932	and
O	933	934	a
O	935	939	food
O	940	949	frequency
O	950	963	questionnaire
O	963	964	.

O	965	969	RBCM
O	970	972	FA
O	973	977	were
O	978	986	analyzed
O	987	989	by
O	990	993	gas
O	994	1008	chromatography
O	1009	1013	with
O	1014	1018	mass
O	1019	1031	spectrometry
O	1031	1032	.

O	1033	1036	The
O	1037	1042	MEDAS
O	1043	1046	was
O	1047	1056	increased
O	1057	1059	in
O	1060	1064	both
O	1065	1071	groups
O	1072	1077	after
O	1078	1079	3
O	1080	1086	months
O	1087	1088	(
O	1088	1090	IG
O	1090	1091	:
O	1092	1093	P
O	1094	1095	<
O	1096	1097	0
O	1097	1098	.
O	1098	1101	001
O	1101	1102	;
O	1103	1105	CG
O	1105	1106	:
O	1107	1108	P
O	1109	1110	=
O	1111	1112	0
O	1112	1113	.
O	1113	1116	004
O	1116	1117	)
O	1117	1118	,
O	1119	1122	and
O	1123	1131	remained
O	1132	1141	increased
O	1142	1146	only
O	1147	1149	in
O	1150	1153	the
O	1154	1156	IG
O	1157	1162	after
O	1163	1165	12
O	1166	1172	months
O	1173	1174	(
O	1174	1175	P
O	1176	1177	<
O	1178	1179	0
O	1179	1180	.
O	1180	1183	001
O	1183	1184	)
O	1184	1185	.

O	1186	1189	The
O	1190	1194	food
O	1195	1204	frequency
O	1205	1218	questionnaire
O	1219	1227	revealed
O	1228	1230	an
O	1231	1240	increased
B-outcome	1241	1247	intake
I-outcome	1248	1250	of
I-outcome	1251	1256	omega
I-outcome	1256	1257	-
I-outcome	1257	1258	3
I-outcome	1259	1260	(
I-outcome	1260	1261	n
I-outcome	1261	1262	-
I-outcome	1262	1263	3
I-outcome	1263	1264	)
I-outcome	1265	1267	FA
I-outcome	1268	1270	at
I-outcome	1271	1276	month
I-outcome	1277	1278	3
I-outcome	1279	1282	and
I-outcome	1283	1288	month
I-outcome	1289	1291	12
O	1292	1294	in
O	1295	1298	the
O	1299	1301	IG
O	1302	1303	(
O	1303	1307	both
O	1308	1309	P
O	1310	1311	<
O	1312	1313	0
O	1313	1314	.
O	1314	1316	01
O	1316	1317	)
O	1317	1318	,
O	1319	1322	but
O	1323	1326	not
O	1327	1329	in
O	1330	1333	the
O	1334	1336	CG
O	1336	1337	,
O	1338	1340	in
O	1341	1346	which
O	1347	1353	intake
O	1354	1356	of
O	1357	1363	energy
O	1363	1364	,
O	1365	1372	protein
O	1373	1376	and
O	1377	1386	saturated
O	1387	1389	FA
O	1390	1399	decreased
O	1399	1400	.

O	1401	1403	In
O	1404	1408	both
O	1409	1415	groups
B-outcome	1416	1417	n
I-outcome	1417	1418	-
I-outcome	1418	1419	6
I-outcome	1420	1422	FA
I-outcome	1423	1425	in
I-outcome	1426	1429	the
I-outcome	1430	1434	RBCM
O	1435	1444	decreased
O	1445	1446	(
O	1446	1447	P
O	1448	1449	<
O	1450	1451	0
O	1451	1452	.
O	1452	1455	001
O	1455	1456	)
O	1456	1457	,
O	1458	1463	while
B-outcome	1464	1465	n
I-outcome	1465	1466	-
I-outcome	1466	1467	9
I-outcome	1468	1470	FA
O	1471	1480	increased
O	1481	1482	(
O	1482	1483	P
O	1484	1485	<
O	1486	1487	0
O	1487	1488	.
O	1488	1491	001
O	1491	1492	)
O	1493	1496	and
B-outcome	1497	1498	n
I-outcome	1498	1499	-
I-outcome	1499	1500	3
I-outcome	1501	1503	FA
O	1504	1508	were
O	1509	1518	unchanged
O	1518	1519	.

O	1520	1525	Women
O	1526	1530	with
O	1531	1537	higher
O	1538	1549	consumption
O	1550	1552	of
O	1553	1557	fish
O	1558	1561	had
O	1562	1568	higher
O	1569	1576	amounts
O	1577	1579	of
B-outcome	1580	1581	n
I-outcome	1581	1582	-
I-outcome	1582	1583	3
I-outcome	1584	1589	fatty
I-outcome	1590	1595	acids
I-outcome	1596	1598	in
I-outcome	1599	1602	the
I-outcome	1603	1607	RBCM
O	1607	1608	.

O	1609	1612	The
O	1613	1618	MEDAS
O	1619	1622	was
O	1623	1632	inversely
O	1633	1643	correlated
O	1644	1648	with
O	1649	1650	n
O	1650	1651	-
O	1651	1652	6
O	1653	1658	fatty
O	1659	1664	acids
O	1664	1665	.

O	1666	1669	The
O	1670	1674	RBCM
O	1675	1677	FA
O	1678	1689	composition
O	1690	1693	was
O	1694	1704	associated
O	1705	1709	with
O	1710	1718	dietetic
O	1719	1729	parameters
O	1730	1737	related
O	1738	1740	to
O	1741	1744	the
O	1745	1749	MedD
O	1749	1750	.

O	1751	1760	Adherence
O	1761	1763	to
O	1764	1767	the
O	1768	1772	MedD
O	1773	1781	resulted
O	1782	1784	in
O	1785	1787	an
O	1788	1795	altered
O	1795	1796	,
O	1797	1803	likely
O	1804	1813	favorable
O	1814	1816	FA
O	1817	1828	composition
O	1828	1829	.

O	1830	1833	Our
O	1834	1838	data
O	1839	1846	suggest
O	1847	1855	selected
O	1856	1858	FA
O	1859	1861	as
O	1862	1872	biomarkers
O	1873	1875	to
O	1876	1883	monitor
O	1884	1894	compliance
O	1895	1897	to
O	1898	1899	a
O	1900	1908	dietetic
O	1909	1921	intervention
O	1922	1926	such
O	1927	1929	as
O	1930	1933	the
O	1934	1938	MedD
O	1938	1939	.

O	1940	1943	The
O	1944	1949	trial
O	1950	1952	is
O	1953	1963	registered
O	1964	1966	at
O	1967	1981	ClinicalTrials
O	1981	1982	.
O	1982	1985	gov
O	1986	1987	(
O	1987	1996	reference
O	1996	1997	:
O	1998	2009	NCT02087592
O	2009	2010	)
O	2010	2011	.
